Division of Molecular Neuroendocrinology, National Institute for Medical Research, The Ridgeway, Mill Hill, London, UK.
Clin Endocrinol (Oxf). 2012 Mar;76(3):387-93. doi: 10.1111/j.1365-2265.2011.04236.x.
Mutations in the POU1F1 gene severely affect the development and function of the anterior pituitary gland and lead to combined pituitary hormone deficiency (CPHD).
The clinical and genetic analysis of a patient presenting with CPHD and functional characterization of identified mutations.
We describe a male patient with extreme short stature, learning difficulties, anterior pituitary hypoplasia, secondary hypothyroidism and undetectable prolactin, growth hormone (GH) and insulin-like growth factor 1 (IGF1), with normal random cortisol.
The POU1F1 coding region was amplified by PCR and sequenced; the functional consequence of the mutations was analysed by cell transfection and in vitro assays.
Genetic analysis revealed compound heterozygosity for two novel putative loss of function mutations in POU1F1: a transition at position +3 of intron 1 [IVS1+3nt(A>G)] and a point mutation in exon 6 resulting in a substitution of arginine by tryptophan (R265W). Functional analysis revealed that IVS1+3nt(A>G) results in a reduction in the correctly spliced POU1F1 mRNA, which could be corrected by mutations of the +4, +5 and +6 nucleotides. Analysis of POU1F1(R265W) revealed complete loss of function resulting from severely reduced protein stability.
Combined pituitary hormone deficiency in this patient is caused by loss of POU1F1 function by two novel mechanisms, namely aberrant splicing (IVS1+3nt (A>G) and protein instability (R265W). Identification of the genetic basis of CPHD enabled the cessation of hydrocortisone therapy without the need for further assessment for evolving endocrinopathy.
POU1F1 基因突变严重影响前垂体腺的发育和功能,导致联合垂体激素缺乏症(CPHD)。
对表现为 CPHD 的患者进行临床和遗传分析,并对鉴定出的突变进行功能特征分析。
我们描述了一名男性患者,其表现为极度身材矮小、学习困难、前垂体发育不良、继发性甲状腺功能减退症和不可检测的催乳素、生长激素(GH)和胰岛素样生长因子 1(IGF1),随机皮质醇正常。
通过 PCR 扩增和测序扩增 POU1F1 编码区;通过细胞转染和体外测定分析突变的功能后果。
遗传分析显示 POU1F1 中存在两种新的推定功能丧失突变的复合杂合性:内含子 1 位置+3 的转换[IVS1+3nt(A>G)]和外显子 6 中的点突变导致精氨酸被色氨酸取代(R265W)。功能分析表明,IVS1+3nt(A>G)导致正确剪接的 POU1F1 mRNA 减少,这可以通过突变+4、+5 和+6 核苷酸来纠正。对 POU1F1(R265W)的分析表明,由于蛋白稳定性严重降低,完全丧失了功能。
该患者的联合垂体激素缺乏症是由两种新的机制引起的 POU1F1 功能丧失引起的,即异常剪接(IVS1+3nt(A>G)和蛋白不稳定(R265W)。CPHD 的遗传基础的确定使得无需进一步评估潜在的内分泌病变即可停止氢化可的松治疗。